Top

Published in:

Open Access 01-12-2013 | Original Paper

Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood

Authors: Veronique V. Belzil, Peter O. Bauer, Mercedes Prudencio, Tania F. Gendron, Caroline T. Stetler, Irene K. Yan, Luc Pregent, Lillian Daughrity, Matthew C. Baker, Rosa Rademakers, Kevin Boylan, Tushar C. Patel, Dennis W. Dickson, Leonard Petrucelli

Published in: Acta Neuropathologica | Issue 6/2013

Abstract

Individuals carrying (GGGGCC) expanded repeats in the C9orf72 gene represent a significant portion of patients suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Elucidating how these expanded repeats cause “c9FTD/ALS” has since become an important goal of the field. Toward this end, we sought to investigate whether epigenetic changes are responsible for the decrease in C9orf72 expression levels observed in c9FTD/ALS patients. We obtained brain tissue from ten c9FTD/ALS individuals, nine FTD/ALS cases without a C9orf72 repeat expansion, and nine disease control participants, and generated fibroblastoid cell lines from seven C9orf72 expanded repeat carriers and seven participants carrying normal alleles. Chromatin immunoprecipitation using antibodies for histone H3 and H4 trimethylated at lysines 9 (H3K9), 27 (H3K27), 79 (H3K79), and 20 (H4K20) revealed that these trimethylated residues bind strongly to C9orf72 expanded repeats in brain tissue, but not to non-pathogenic repeats. Our finding that C9orf72 mRNA levels are reduced in the frontal cortices and cerebella of c9FTD/ALS patients is consistent with trimethylation of these histone residues, an event known to repress gene expression. Moreover, treating repeat carrier-derived fibroblasts with 5-aza-2-deoxycytidine, a DNA and histone demethylating agent, not only decreased C9orf72 binding to trimethylated histone residues, but also increased C9orf72 mRNA expression. Our results provide compelling evidence that trimethylation of lysine residues within histones H3 and H4 is a novel mechanism involved in reducing C9orf72 mRNA expression in expanded repeat carriers. Of importance, we show that mutant C9orf72 binding to trimethylated H3K9 and H3K27 is detectable in blood of c9FTD/ALS patients. Confirming these exciting results using blood from a larger cohort of patients may establish this novel epigenetic event as a biomarker for c9FTD/ALS.

Available only for authorised users

Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, Sandi C et al (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17(5):735–746PubMedCrossRef

Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77(4):639–646PubMedCrossRef

Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129(4):823–837PubMedCrossRef

Bauer PO, Zumrova A, Matoska V, Mitsui K, Goetz P (2004) Can ataxin-2 be down-regulated by allele-specific de novo DNA methylation in SCA2 patients? Med Hypotheses 63(6):1018–1023PubMedCrossRef

Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78(2):547–581PubMed

Belzil VV, Gendron TF, Petrucelli L (2012) RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci 56C:406–419

Bradley WG (2000) Neurology in clinical practice, 3rd edn. Butterworth-Heinemann, Boston

Braunschweig D, Simcox T, Samaco RC, LaSalle JM (2004) X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2∓ mouse brain. Hum Mol Genet 13(12):1275–1286PubMedCrossRef

Caiafa P, Zampieri M (2005) DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem 94(2):257–265PubMedCrossRef

10.

Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10(5):295–304PubMedCrossRef

11.

Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, Zeiher AM et al (2013) Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci 14(9):17643–17663PubMedCrossRef

12.

Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 8(1):28PubMedCrossRef

13.

Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ (2011) Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 31(46):16619–16636PubMedCrossRef

14.

Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A et al (2013) Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. doi:10.1002/ana.23946 PubMed

15.

Cong SY, Pepers BA, Zhou TT, Kerkdijk H, Roos RA, van Ommen GJ et al (2012) Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway. Neurobiol Dis 46(3):673–681PubMedCrossRef

16.

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72(2):245–256PubMedCrossRef

17.

Fraga MF, Esteller M (2007) Epigenetics and aging: the targets and the marks. Trends Genet 23(8):413–418PubMedCrossRef

18.

Galimberti D, D’Addario C, Dell’osso B, Fenoglio C, Marcone A, Cerami C et al (2013) Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol Sci 34(6):899–903PubMedCrossRef

19.

Galimberti D, Scarpini E (2010) Genetics and biology of Alzheimer’s disease and frontotemporal lobar degeneration. Int J Clin Exp Med 3(2):129–143PubMed

20.

Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196(2):261–282PubMedCrossRef

21.

Gendron TF, Cosio DM, Petrucelli L (2013) c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. Expert Opin Ther Targets 17(9):991–995PubMedCrossRef

22.

Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G et al (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11(1):54–65PubMedCrossRef

23.

Giordana MT, Ferrero P, Grifoni S, Pellerino A, Naldi A, Montuschi A (2011) Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. Neurol Sci 32(1):9–16PubMedCrossRef

24.

Graff-Radford NR, Woodruff BK (2007) Frontotemporal dementia. Semin Neurol 27(1):48–57PubMedCrossRef

25.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10(10):1003–1005PubMedCrossRef

26.

Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D et al (2006) Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 253(12):1642–1643PubMedCrossRef

27.

Laffita-Mesa JM, Bauer PO, Kouri V, Pena Serrano L, Roskams J, Almaguer Gotay D et al (2012) Epigenetics DNA methylation in the core ataxin-2 gene promoter: novel physiological and pathological implications. Hum Genet 131(4):625–638PubMedCrossRef

28.

Lomen-Hoerth C, Anderson T, Miller B (2002) The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59(7):1077–1079PubMedCrossRef

29.

Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, Kretzschmar H et al (2013) hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol 125(3):413–423PubMedCrossRef

30.

Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339(6125):1335–1338PubMedCrossRef

31.

Murgo AJ (2005) Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin Oncol 32(5):458–464PubMedCrossRef

32.

Nasrallah MP, Cho G, Simonet JC, Putt ME, Kitamura K, Golden JA (2012) Differential effects of a polyalanine tract expansion in Arx on neural development and gene expression. Hum Mol Genet 21(5):1090–1098PubMedCrossRef

33.

Oki Y, Issa JP (2006) Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1(2):169–182PubMedCrossRef

34.

Prell T, Grosskreutz J (2013) The involvement of the cerebellum in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (Epub ahead of print)

35.

Renoux AJ, Todd PK (2012) Neurodegeneration the RNA way. Prog Neurobiol 97(2):173–189PubMedCrossRef

36.

Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72(2):257–268PubMedCrossRef

37.

Santoro MR, Bray SM, Warren ST (2012) Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 7:219–245PubMedCrossRef

38.

Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH (2002) Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem 277(42):39195–39201PubMedCrossRef

39.

Stadtman ER (1992) Protein oxidation and aging. Science 257(5074):1220–1224PubMedCrossRef

40.

Stoger R, Kajimura TM, Brown WT, Laird CD (1997) Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet 6(11):1791–1801PubMedCrossRef

41.

Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, Min KT et al (2010) Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet 6(12):e1001240PubMedCrossRef

42.

Wang CM, Tsai SN, Yew TW, Kwan YW, Ngai SM (2010) Identification of histone methylation multiplicities patterns in the brain of senescence-accelerated prone mouse 8. Biogerontology 11(1):87–102PubMedCrossRef

43.

Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C et al (2013) Hypermethylation of the CpG island near the GC repeat in ALS with a C9orf72 expansion. Am J Hum Genet (Epub ahead of print)

44.

Zhao W, Beers DR, Appel SH (2013) Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 8(4):888–899PubMedCrossRef

Title: Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood
Authors: Veronique V. Belzil
Peter O. Bauer
Mercedes Prudencio
Tania F. Gendron
Caroline T. Stetler
Irene K. Yan
Luc Pregent
Lillian Daughrity
Matthew C. Baker
Rosa Rademakers
Kevin Boylan
Tushar C. Patel
Dennis W. Dickson
Leonard Petrucelli
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 6/2013
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-013-1199-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins

Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration

Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS

Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations

C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci

Making sense of the antisense transcripts in C9FTD/ALS